Download News Release

News Release
________________________________________________________
The Hebrew University of Jerusalem
‫האוניברסיטה העברית בירושלים‬
‘LEGO-Like’ Building Blocks to Halt Cell Growth Wins
Kaye Prize for Hebrew University Ph.D. Student
Jerusalem, June 7, 2006—A method for delivery of drugs to targeted cells through the
design of specific molecular structures called SIB (Small Integrated Building Blocks)
has won a prestigious scientific prize for a Ph.D. student in organic chemistry at the
Hebrew University of Jerusalem.
Jerusalemite Nir Qvit, 34, will be one of those receiving the Kaye Innovation Award
on June 13, during the 69th meeting of the Hebrew university Board of Governors.
Qvit has shown through his research that it is possible to greatly increase drug
delivery efficiency by designing specific molecular structures made up of known
pharmaceutically effective peptides (small protein molecules) that are attached to
tailor-made, geometric-like structures called “scaffolding.”
Each scaffold is specifically designed to combine the peptides in such a way that they
will form an effective medicinal combination and so that they will bind to the
receptors of specific targeted cells. Qvit refers to his process as somewhat analogous
to building different kinds of structures through the use of LEGO.
Qvit, a student of Prof. Chaim Gilon of the Department of Organic Chemistry, has
shown, for example, that with a particular combination of peptides and scaffold
design, it is possible to create a synthetic molecule that will bind to the IGF-1
(insulin-like growth factor-1) receptor. IGF-1 is a protein that plays a critical role in
the proliferation of many cancers, including prostate, lung, breast, colon and brain
cancers. The binding action of the molecule to the receptor inhibits the activation of
the IGF-1 protein in the cells, thus halting the cancerous growth.
Through this process of “combinational chemistry,” involving peptides and scaffold
design, Qvit says that many different types of molecules can be built that will reach
specifically targeted cells, offering hope for treatment of not only cancer, but other
diseases as well, without harming healthy cells.
The Kaye Innovation Awards have been given annually since 1994. Isaac Kaye of
England, a prominent industrialist in the pharmaceutical industry, established the
awards to encourage faculty, staff, and students of the Hebrew University to develop
innovative methods and inventions with good commercial potential which will benefit
the university and society.
(Photo available via e-mail upon request)
For further information:
Jerry Barach, Dept. of Media Relations, the Hebrew University, Tel: 02-588-2904,
or Orit Sulitzeanu, Hebrew University spokesperson, Tel: 02-5882910.
Internet site: http://media.huji.ac.il.